Plasma phospholipid transfer protein activity is independently determined by obesity and insulin resistance in non-diabetic subjects

Atherosclerosis

Volumn 217, Issue 1, 2011, Pages 253-259

  de Vries, Rindert ^a   Kappelle, Paul J W H ^a   Dallinga Thie, Geesje M ^b   Dullaart, Robin P F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

HOMAir; Insulin resistance; Obesity; Phospholipid transfer protein; Waist circumference; Waist to hip ratio

Indexed keywords

APOLIPOPROTEIN A1; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; PHOSPHOLIPID TRANSFER PROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

ADIPOSITY; ADULT; AGED; BODY MASS INDEX; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INSULIN RESISTANCE; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; OBESITY; PHOSPHOLIPID TRANSFER PROTEINS; RISK FACTORS; WAIST CIRCUMFERENCE;

EID: 79960216442     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.03.021     Document Type: Article

References (37)

1. Vergeer M., Dallinga-Thie G.M., Dullaart R.P.F., van Tol A. Evaluation of phospholipid transfer protein as a therapeutic target. Fut Lipidol 2008, 3:327-335.
2. Borggreve S.E., de Vries R., Dullaart R.P.F. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003, 33:1051-1069.
3. Tzotzas T., Desrumaux C., Lagrost L. Plasma phospholipid transfer protein (PLTP): review of an emerging cardiometabolic risk factor. Obes Rev 2009, 10:403-411.
4. Schlitt A., Liu J., Yan D., et al. Anti-inflammatory effects of phospholipid transfer protein (PLTP) deficiency in mice. Biochim Biophys Acta 2005, 1733:187-191.
5. Cheung M.C., Vaisar T., Han X., Heinecke J.W., Albers J.J. Phospholipid transfer protein in human plasma associates with proteins linked to immunity and inflammation. Biochemistry 2010, 49:7314-7322.
6. Cheung M.C., Brown B.G., Marino Larsen E.K., et al. Phospholipid transfer protein activity is associated with inflammatory markers in patients with cardiovascular disease. Biochim Biophys Acta 2006, 1762:131-137.
7. Tan K.C., Shiu S.W., Wong Y., Tam S. Plasma phospholipid transfer protein activity and subclinical inflammation in type 2 diabetes mellitus. Atherosclerosis 2005, 178:365-370.
8. Schgoer W., Mueller T., Jauhiainen M., et al. Low phospholipid transfer protein (PLTP) is a risk factor for peripheral atherosclerosis. Atherosclerosis 2008, 196:219-226.
9. Schlitt A., Bickel C., Thumma P., et al. High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2003, 23:1857-1862.
10. de Vries R., Dallinga-Thie G.M., Smit A.J., et al. Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus. Diabetologia 2006, 49:398-404.
11. Schlitt A., Blankenberg S., Bickel C., et al. PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene study. J Lipid Res 2009, 50:723-729.
12. Jarvik G.P., Rajagopalan R., Rosenthal E.A., et al. Genetic and nongenetic sources of variation in phospholipid transfer protein activity. J Lipid Res 2010, 51:983-990.
13. Kathiresan S., Willer C.J., Peloso G.M., et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 2009, 41:56-65.
14. Vergeer M., Boekholdt S.M., Sandhu M.S., et al. Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipoprotein size and is a novel marker of cardiovascular disease susceptibility. Circulation 2010, 122:470-477.
15. Dullaart R.P.F., Sluiter W.J., Dikkeschei L.D., Hoogenberg K., Van Tol A. Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur J Clin Invest 1994, 24:188-194.
16. Desrumaux C., Athias A., Bessède G., et al. Mass concentration of plasma phospholipid transfer protein in normolipidemic, type IIa hyperlipidemic, type IIb hyperlipidemic, and non-insulin-dependent diabetic subjects as measured by a specific ELISA. Arterioscler Thromb Vasc Biol 1999, 19:266-275.
17. Riemens S.C., van Tol A., Sluiter W.J., Dullaart R.P.F. Plasma phospholipid transfer protein activity is related to insulin resistance: impaired acute lowering by insulin in obese Type II diabetic patients. Diabetologia 1998, 41:929-934.
18. Kaser S., Sandhofer A., Föger B., et al. Influence of obesity and insulin sensitivity on phospholipid transfer protein activity. Diabetologia 2001, 44:1111-1117.
19. Murdoch S.J., Kahn S.E., Albers J.J., Brunzell J.D., Purnell J.Q. PLTP activity decreases with weight loss: changes in PLTP are associated with changes in subcutaneous fat and FFA but not IAF or insulin sensitivity. J Lipid Res 2003, 44:1705-1712.
20. Dullaart R.P.F., de Vries R., Dallinga-Thie G.M., van Tol A., Sluiter W.J. Plasma cholesteryl ester transfer protein mass and phospholipid transfer protein activity are associated with leptin in type 2 diabetes mellitus. Biochim Biophys Acta 2007, 1771:113-118.
21. Laimer M.W., Engl J., Tschoner A., et al. Effects of weight loss on lipid transfer proteins in morbidly obese women. Lipids 2009, 44:1125-1130.
22. Tzotzas T., Dumont L., Triantos A., et al. Early decreases in plasma lipid transfer proteins during weight reduction. Obesity (Silver Spring) 2006, 14:1038-1045.
23. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752. American Heart Association; National Heart, Lung, and Blood Institute.
24. Speijer H., Groener J.E., van Ramshorst E., van Tol A. Different locations of cholesteryl ester transfer protein and phospholipid transfer protein activities in plasma. Atherosclerosis 1991, 90:159-168.
25. Cnop M., Landchild M.J., Vidal J., et al. The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: distinct metabolic effects of two fat compartments. Diabetes 2002, 51:1005-1015.
26. Janssen I., Katzmarzyk P.T., Ross R. Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr 2004, 79:379-384.
27. Fox C.S., Massaro J.M., Hoffmann U., et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007, 116:39-48.
28. Julius U., Jauhiainen M., Ehnholm C., Pietzsch J. Lipid transfer protein activities in subjects with impaired glucose tolerance. Clin Chem Lab Med 2007, 45:237-244.
29. Riemens S.C., van Tol A., Sluiter W.J., Dullaart R.P.F. Plasma phospholipid transfer protein activity is lowered by 24-h insulin and acipimox administration: blunted response to insulin in type 2 diabetic patients. Diabetes 1999, 48:1631-1637.
30. Riemens S.C., Van Tol A., Sluiter W.J., Dullaart R.P.F. Acute and chronic effects of a 24-hour intravenous triglyceride emulsion challenge on plasma lecithin: cholesterol acyltransferase, phospholipid transfer protein, and cholesteryl ester transfer protein activities. J Lipid Res 1999, 40:1459-1466.
31. Goldstein J.L., Brown M.S., Liang G. LXR-SREBP-1c-phospholipid transfer protein axis controls very low density lipoprotein (VLDL) particle size. J Biol Chem 2010, 285:6801-6810.
32. Cao G., Beyer T.P., Yang X.P., et al. Phospholipid transfer protein is regulated by liver X receptors in vivo. J Biol Chem 2002, 277:39561-39565.
33. Tu A.Y., Albers J.J. Glucose regulates the transcription of human genes relevant to HDL metabolism: responsive elements for peroxisome proliferator-activated receptor are involved in the regulation of phospholipid transfer protein. Diabetes 2001, 50:1851-1856.
34. Dullaart R.P.F., Hoogenberg K., Dikkeschei L.D., van Tol A. Higher plasma lipid transfer protein activities and unfavorable lipoprotein changes in cigarette-smoking men. Arterioscler Thromb 1994, 14:1581-1585.
35. Oomen P.H., van Tol A., Hattori H., et al. Human plasma phospholipid transfer protein activity is decreased by acute hyperglycaemia: studies without and with hyperinsulinaemia in Type 1 diabetes mellitus. Diabet Med 2005, 22:768-774.
36. Janssen I., Katzmarzyk P.T., Ross R. Body mass index, waist circumference, and health risk: evidence in support of current National Institutes of Health guidelines. Arch Intern Med 2002, 162:2074-2079.
37. Luo Y., Shelly L., Sand T., et al. Pharmacologic inhibition of phospholipid transfer protein activity reduces apolipoprotein-B secretion from hepatocytes. J Pharmacol Exp Ther 2010, 332:1100-1106.